Tout DSpace

Parcourir par sujet "STAT5 protein"

Voici les éléments 1-4 de 4

    • An Activating Janus kinase-3 mutation is associated with cytotoxic T lymphocyte antigen-4-dependent Immune dysregulation syndrome 

      Sic H., Speletas M., Cornacchione V., Seidl M., Beibel M., Linghu B., Yang F., Sevdali E., Germenis A.E., Oakeley E.J., Vangrevelinghe E., Sailer A.W., Traggiai E., Gram H., Eibel H. (2017)
      Heterozygous mutations in the cytotoxic T lymphocyte antigen-4 (CTLA-4) are associated with lymphadenopathy, autoimmunity, immune dysregulation, and hypogammaglobulinemia in about 70% of the carriers. So far, the incomplete ...

    • Microbiome in multiple sclerosis; where are we, what we know and do not know 

      Boziki M.K., Kesidou E., Theotokis P., Mentis A.-F.A., Karafoulidou E., Melnikov M., Sviridova A., Rogovski V., Boyko A., Grigoriadis N. (2020)
      An increase of multiple sclerosis (MS) incidence has been reported during the last decade, and this may be connected to environmental factors. This review article aims to encapsulate the current advances targeting the study ...

    • On the immunoregulatory role of statins in multiple sclerosis: the effects on Th17 cells 

      Ntolkeras G., Barba C., Mavropoulos A., Vasileiadis G.K., Dardiotis E., Sakkas L.I., Hadjigeorgiou G., Bogdanos D.P. (2019)
      Statins, the cholesterol-lowering drugs, also possess immunomodulatory properties, affecting among others T cell activation and differentiation, antigen presentation, and regulatory T cell (Tregs) maintenance and ...

    • Upadacitinib tartrate in rheumatoid arthritis 

      Stamatis P., Bogdanos D.P., Sakkas L.I. (2020)
      does not achieve low disease activity or remission despite the use of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and/or biological DMARDs (bDMARDs). The Janus kinase (JAK) inhibitors are the ...